Patents by Inventor Kristen Hege

Kristen Hege has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF
    Publication number: 20230190798
    Abstract: Provided in some aspects are compositions of cells for treating subjects with disease and conditions such as non-Hodgkin's lymphoma (NHL), and related methods, compositions, uses and articles of manufacture. In some embodiments, the disease or condition is a B-cell non-Hodgkin lymphoma (B-cell NHL). The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) for targeting an antigen, such as CD 19, on cells of the lymphoma.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 22, 2023
    Applicant: Juno Therapeutics, Inc.
    Inventors: Matthew WESTOBY, Adrian Wrangham BRIGGS, David G. KUGLER, Robert Guy CASPARY, Calvin CHAN, Divya VARUN, Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Keenan BASHOUR, Oleksandr BATUREVYCH, Nurgul KILAVUZ, Kristen HEGE, Michael BURGESS, Kaida WU, Ruth Amanda SALMON
  • BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF
    Publication number: 20230087953
    Abstract: Provided in some aspects are compositions of cells for treating subjects with disease and conditions such as multiple myeloma (MM), and related methods, compositions, uses and articles of manufacture. In some embodiments, the disease or condition is a relapsed or refractory multiple myeloma (r/r MM). The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) for targeting an antigen, such as BCMA, on cells of the myeloma.
    Type: Application
    Filed: February 11, 2021
    Publication date: March 23, 2023
    Applicant: Juno Therapeutics, Inc.
    Inventors: Matthew WESTOBY, Adrian Wrangham BRIGGS, David G. KUGLER, Robert Guy CASPARY, Calvin CHAN, Divya VARUN, Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Keenan BASHOUR, Oleksandr BATUREVYCH, Nurgul KILAVUZ, Kristen HEGE, Michael BURGESS, Kaida WU, Ruth Amanda SALMON, Ashley KOEGEL
  • METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3
    Publication number: 20230057602
    Abstract: The present invention relates to methods of treating a patient having a disorder associated with BCMA expression (e.g. BCMA-expressing B-cell cancers, such as multiple myeloma) using dose-escalation dosing regimens with multispecific (e.g. bispecific) antibodies that bind to CD3 and BCMA.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 23, 2023
    Inventors: Michael BURGESS, Kristen HEGE, Kaushik DATTA, Isaac BOSS, Minh Diem VU
  • CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210371522
    Abstract: CD47 antibodies that specifically inhibit the interaction between CD47 and the CD47-signal regulatory protein alpha (SIRP?) but not the interaction between CD47 and thrombospondin-1 (TSP-1), and methods of using these monoclonal antibodies as therapeutics are provided.
    Type: Application
    Filed: August 2, 2021
    Publication date: December 2, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Pilgrim Jackson, Laure Escoubet, Kandasamy Hariharan, Michael Burgess, Kristen Hege, Heather Raymon, Piu Wong
  • USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20210330788
    Abstract: The invention provides uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 28, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Kristen HEGE, Payal PATEL, Steven NOVICK, Lars STERNAS
  • USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20210128619
    Abstract: Provided herein are uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicants: CELGENE CORPORATION, JUNO THERAPEUTICS, INC., BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Timothy CAMPBELL, Ronald HAUSE, Kristen HEGE, Yue JIANG, Shari KAISER, Ethan THOMPSON, Jaymes FULLER, Nathan MARTIN, Rong LIU, Justine DELL'ARINGA
  • CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200255515
    Abstract: Integrin-associated protein (IAP or CD47) antibodies that specifically inhibit the interaction between CD47 and the CD47-signal regulatory protein alpha (SIRPa) but not the interaction between CD47 and thrombospondin-1 (TSP-1), and methods of using these monoclonal antibodies as therapeutics are provided. Further disclosed are sequences of variable heavy chains and variable light chains of the antibodies provided.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 13, 2020
    Inventors: Victoria Sung, Pilgrim Jackson, Laure Escoubet, Kandasamy Hariharan, Michael Burgess, Kristen Hege, Heather Raymon, Piu Wong